PROTECTION OF THE HAIR CELLS FROM THE OTOTOXIC EFFECT OF STREPTOMYCIN by Aman, Maharjan et al.
    Int. J. Ayur. Pharma Research, 2015;3(1):24-36       ISSN: 2322 - 0910 
 
 Available online at : http://ijapr.in Page 24 
International Journal of Ayurveda and Pharma Research  
          Review Article 
 
PROTECTION OF THE HAIR CELLS FROM THE OTOTOXIC EFFECT OF STREPTOMYCIN  
Maharjan Aman1*, Mollah Muzammal Hoque1, Yadav Shashi Bhushan1, M.A.A Fathima1, P.K.M. 
Naagrathna2  
*1P.G. Scholar, 2Assistant Professor, Department of Pharmacology, Karnataka College of Pharmacy, 
Bangalore, Karnataka, India. 
Received on: 05/01/2014         Revised on: 16/01/2015                  Accepted on: 27/01/2015 
ABSTRACT 
Ototoxicity is the property of being toxic to the ear (oto-), specifically the cochlea or auditory 
nerve and sometimes the vestibular system; it is commonly medication-induced. It has long 
been known that the major irreversible toxicity of aminoglycosides is ototoxicity. In many 
developing countries, where drugs such as the aminoglycosides are frequently prescribed to 
treat pneumonia, diarrhoea, and tuberculosis, the incidence of ototoxicity is high. Physicians 
in practice need to recognize that ototoxic drugs can cause significant auditory and in many 
instances, poorly recognized, vestibular toxicity. 
  Aminoglycosides can cause eighth cranial nerve damage, resulting in vestibular 
and/or auditory toxicities. Aminoglycosides appear to generate free radicals within the inner 
ear, with subsequent permanent damage to sensory cells and neurons, resulting in permanent 
hearing loss. Two mutations in the mitochondrial 12S ribosomal RNA gene have been 
previously reported to predispose carriers to aminoglycoside-induced ototoxicity. 
  As aminoglycosides are indispensable agents both in the treatment of infections and 
Meniere's disease, a great effort has been made to develop strategies to prevent 
aminoglycoside ototoxicity. 
  Efforts have been made against streptomycin toxicity using corticosteroid and 
Caffeic acid phenethyl ester. Chemicals are being evaluated for their ability to prevent 
ototoxicity and that might be prescribed in tandem with ototoxic drugs in the future. 
Investigators are also studying methods of hair-cell and nerve-cell regeneration. 
KEYWORDS: Ototoxicity, Cause of ototoxicity, Symptoms, Efforts in hair cell protection, 
Treatment for ototoxicity 
INTRODUCTION
Ototoxicity is, quite simply, ear poisoning 
(oto = ear, toxicity = poisoning), which results 
from exposure to drugs or chemicals that damage 
the inner ear or the vestibulo-cochlear nerve (the 
nerve sending balance and hearing information 
from the inner ear to the brain). Because the 
inner ear is involved in both hearing and balance, 
ototoxicity can result in disturbances of either or 
both of these senses. The parts of the brain that 
receive hearing and balance information from the 
inner ear can also be affected by poison, but this 
is not technically considered ototoxicity and 
won’t be covered in this information sheet 
(Poisoning of the brain is classified as 
neurotoxicity).[1] 
 The occurrence and degree of inner ear 
poisoning depends upon the drug involved as 
well as other factors such as heredity. Ototoxicity 
can be temporary or permanent. The effect of 
certain drugs is often temporary, while other 
drugs typically produce permanent changes to 
the ear. Some drugs can cause either temporary 
or permanent problems. It is important to note 
here that the broad majority of people who 
experience ototoxicity have a temporary or 
reversible form that does not result in a major or 
long-term disruption in their lives.[2] 
 With cochleotoxicity, hearing loss or the 
start or worsening of tinnitus (ringing in the 
ears) can occur through damage to the cochlea 
(the hearing apparatus) or the cochlear branch of 
the vestibulo-cochlear nerve. Vestibular 
ototoxicity or vestibulotoxicity are terms used to 
describe ototoxicity that affects the balance 
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organs or the vestibular branch of the vestibulo-
cochlear nerve.[2] 
 It is important to note that no drug is 
known to cause Ménière’s disease, benign 
paroxysmal positional vertigo, or any other 
vestibular disorder causing fluctuating function.[2] 
How common is ototoxicity?[3] 
 No one knows how many people suffer 
from ototoxicity each year or the percentage of 
vestibular disorders caused by ototoxicity. What 
is known is that when permanent and extensive 
ototoxicity occurs, the effects can take a terrible 
toll on a person’s ability to function. 
Cause of ototoxicity 
 Scientific studies are required to confirm 
whether a drug is ototoxic. Unfortunately, such 
research often involves years of study. When 
assessing the safety of a drug prior to releasing it 
on the market, the U.S. Food and Drug 
Administration does not require testing of inner 
ear function or examination of the inner ear 
structures. This is one reason it is almost 
impossible to say with confidence how many and 
which drugs cause ototoxicity and how many or 
which people are affected by it. 
 Problems with a particular drug are 
usually only discovered after enough people have 
suffered the consequences and when physicians 
or other health care professionals can see a 
probable connection between the symptoms or 
problems and a drug. This was the case with 
aspirin and quinine centuries ago, with the 
antibiotic streptomycin in the 1940s, and more 
recently with some anti-cancer drugs. Since then, 
scientific studies have shown that these drugs 
cause ototoxicity in animals and people. Other, 
newer drugs have been implicated as ototoxic as 
well, but solid scientific proof is often lacking.[4] 
 Many chemicals have ototoxic potential, 
including over-the-counter drugs, prescription 
medications, and environmental chemicals. The 
information below includes substances thought 
to cause ototoxicity. The discussion is incomplete 
because of the limited research thus far.  
Note: if you are taking drugs on the advice of 
your physician, DO NOT STOP TAKING THEM 
just because you see them listed here! Speak 
with your doctor about your concerns to 
determine the best choice in your own unique 
situation. 
Aspirin and quinine Aspirin (acetylsalicylic acid, 
ASA) and quinine are well known to cause 
temporary ototoxicity resulting in tinnitus. They 
may also reduce hearing, particularly when given 
at high doses. Quinine products can also 
temporarily reduce balance ability. Once aspirin 
or quinine is stopped, the ototoxicity generally 
disappears. Some quinine products include:[5,6] 
 chloroquine 
 quinidine 
 quinine (including Q-vel) 
 tonic water 
Loop diuretics are a specific family of “water 
pills” that is known to occasionally cause 
temporary ototoxicity. These drugs cause ringing 
in the ears or decreased hearing that reverses 
when the drug is stopped. 
 An increased probability of ototoxicity is 
thought to occur with loop diuretics when they 
are administered during the same time period 
that an aminoglycoside antibiotic (see next 
section) is given. The loop diuretics include:[6,7] 
 bumetanide (Bumex) 
 ethacrynic acid (Edecrin) 
 furosemide (Lasix) 
 torsemide (Demadex) 
Note: Hydrochlorothiazide (HCTZ) and Maxide 
diuretics commonly prescribed to people with 
Ménière’s disease or other forms of 
endolymphatic hydrops are not loop diuretics. 
Aminoglycoside antibiotics All members of the 
aminoglycoside antibiotic family are well known 
for their potential to cause permanent ototoxicity 
if they enter the inner ear. Some of these drugs 
are more likely to cause hearing loss; others are 
more likely to cause vestibular loss. Others can 
cause either problem. 
A higher risk for aminoglycoside 
antibiotic induced ototoxicity occurs when a 
person receives concurrent ototoxic drugs (such 
as a loop diuretic or another antibiotic 
vancomycin), has insufficient kidney function or 
is receiving a drug that causes insufficient kidney 
function, or has a genetic vulnerability. 
 The risk of ototoxicity also increases with 
an increasing amount of the drug that enters the 
blood stream, the longer the drug is in the body, 
and the duration of time the drug is taken. 
Aminoglycoside antibiotics can enter the inner 
ear through the blood system or via diffusion 
from the middle ear into the inner ear. They enter 
the blood stream in largest amounts when given 
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intravenously (by IV) and in the least amounts by 
pill. Inhaled drugs also enter the blood stream; an 
example of this is the use of inhaled tobramycin 
for long-term treatment of cystic fibrosis. 
 Can ear drops containing 
aminoglycosides be problematic? If they find 
their way into the middle ear in large enough 
quantities, such ear drops can diffuse into the 
inner ear and cause damage. Physicians do not 
agree about how often and under what 
circumstances this occurs. Many papers in 
medical journals address this argument. 
Members of the aminoglycoside family 
include:[7,8,9,10] 
 amikacin 
 netilmicin 
 dihydrostreptomycin 
 ribostamycin 
 gentamicin 
 streptomycin 
 kanamycin 
 tobramycin 
 neomycin 
Anti-neoplastics (anti-cancer drugs) 
Anti-cancer drugs work by killing cancer cells. 
Unfortunately some can also damage or kill cells 
elsewhere in the body, including the ears. 
Cisplatin is well known to cause massive and 
permanent hearing loss. Carboplatin is also 
known to be ototoxic.[9,10] 
Environmental chemicals have long been 
implicated in ototoxicity. Little research has been 
done to substantiate their precise effect on ears, 
but most are associated with hearing 
disturbances that may be permanent. In addition, 
mercury has also been linked to permanent 
balance problems. These include:[9,10] 
 butyl nitrite 
 mercury 
 carbon disulfide 
 styrene 
 carbon monoxide 
 tin 
 hexane 
 toluene 
 lead 
 trichloroethylene 
 manganese 
 xylene 
What damage occurs?[11,12] 
 Two areas can be damaged or destroyed 
through ototoxicity: the hair cells within the 
inner ear, and the vestibulo-cochlear nerve that 
links the inner ear to the brain. When damage 
occurs, any degree and combination of hearing 
loss and balance disruption are possible 
depending upon the part(s) affected. 
 Hair cells are located in both the cochlea 
and the vestibular areas of the inner ear. They are 
composed of a cell body with a hair-like 
attachment. When these “hairs” are normally 
bent with sound vibrations or movement, they 
send electrical signals to the brain about hearing 
or balance function. In ototoxicity, these hairs can 
be damaged to the point that they no longer stand 
up, thus reducing the auditory and/or balance 
signals sent to the brain. 
Symptoms of ototoxicity[13] 
 Cochleotoxicity symptoms range from 
mild tinnitus to total hearing loss, depending 
upon each person and the form and level of 
exposure to the ototoxin. They can include one-
sided or two-sided hearing loss and constant or 
fluctuating tinnitus. 
 Vestibulotoxicity symptoms range from 
mild imbalance to total incapacitation. Symptoms 
of a vestibular or balance function loss depend 
upon the degree of damage, if the damage 
occurred rapidly or slowly, if it’s one-sided or 
two-sided, and how long ago the damage 
occurred. A slow one-sided loss might not 
produce any symptoms, while a rapid loss could 
produce enough vertigo, vomiting, and 
nystagmus (eye jerking), to keep a person in bed 
for days. Most of the time, the symptoms slowly 
pass, allowing a person to return to normal 
activities. 
 A two-sided loss in vestibulotoxicity 
typically causes headache, a feeling of ear 
fullness, imbalance to the point of being unable to 
walk, and a bouncing and blurring of vision 
(oscillopsia) rather than intense vertigo, 
vomiting, and nystagmus. It also tends to produce 
inability to tolerate head movement, a wide-
based gait (walking with the legs farther apart 
than usual), difficulty walking in the dark, 
unsteadiness or the sensation of unsteadiness, 
lightheadedness, and significant fatigue. If the 
damage is severe, symptoms such as oscillopsia 
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and problems with walking in the dark or with 
the eyes closed will not diminish with time. 
Ototoxicity and mechanism of hair cell 
damage 
Susceptibility and Genetic Predisposition for 
Aminoglycoside Ototoxicity 
  While AGs preferentially target the 
bacterial ribosome, the inner ear and kidney are 
known to receive collateral damage in many 
patients receiving treatment[14,15]. However, a 
meta-analysis comparing once versus multiple-
daily regimens of different AGs could not 
determine a statistical significant correlation 
between ototoxicity and treatment regimens[16]. 
One main susceptibility factor (17%–33% of 
patients with reported ototoxic damage[17]) is the 
genetic predisposition to AG ototoxicity[18]. The 
fact that this increased susceptibility was 
inherited maternally suggested mitochondrial 
involvement[18]. This is compelling in light of the 
endosymbiotic theory as mitochondrial 
ribosomes demonstrate more similarities to 
prokaryotic ribosomes than cytosolic ribosomes 
[19,20]. Therefore, the small subunit of the 
mitochondrial ribosome is one of the primary 
targeting sites for AGs[21,22]. Several mutations in 
mitochondrial DNA are linked to increased 
susceptibility to AG ototoxicity [17,23,24]. Exposure 
to AG leads to impairment of RNA translation 
within mitochondria through interaction with 
binding sites on mitochondrial 12S rRNA[23]. This 
interaction was mapped to an adenine-to-guanine 
mutation at nucleotide 1555 in the 12S rRNA 
gene[23]. Of additional note, bacterial resistance 
mutations are described at this locus[25,26]. This 
mutation increases structural similarity of 
mitochondrial rRNA to bacterial rRNA[23], which 
promotes binding of AG to mutated 
mitochondrial 12S rRNA[26,27]. As a result, damage 
can result from decreased protein synthesis[26]. 
 Although no direct evidence exists to link 
ototoxicity to an inhibition of mitochondrial 
protein synthesis, inhibition of mitochondrial 
protein synthesis potentiates AG toxicity[28]. Also, 
electron microscopy reveals mitochondrial 
disruption following AG treatment[29]. This 
susceptibility mutation has been reported in 
17%– 33% of patient with reported AG 
ototoxicity[17]; in the general population of the 
European Union, it is estimated to be 1 : 500[30,31]. 
Other mutations leading to increased AG 
susceptibility have also been described, including 
C1494T[24]. The C1494T mutations have varying 
degrees of penetrance[32], are less common than 
the A1555G mutation[33], and are sporadic with 
multiple origins[34]. In sum, the prevalence of the 
most common mutations across varying ethnic 
backgrounds is 0.9%–1.8%[33,35], of which 5%-6% 
are sporadic[19,36,37]. 
 Although this genetic susceptibility is 
present in all organs, the mitochondrial 
mutations target the cochlea but not the 
vestibular organs or the kidneys[39]. This is 
intriguing as this selective cochleotoxicity also 
occurs with preferably vestibulotoxic AGs such as 
streptomycin[39]. One proposed explanation for 
this phenomenon is that AGs cause misreading in 
mitochondrial protein synthesis rather than 
direct inhibition of protein synthesis[39] such that 
tissues rich in mitochondria would be 
predominately affected[38]. 
 Exposure to AGs would decrease 
mitochondrial ATP synthesis resulting in 
compromised ion pump activity[38,39]. Reduced 
ion pump activity in strial intermediate cells 
could ultimately lead to a progressive decrease of 
the endocochlear potential[38]. This scenario 
conceivably explains the slow progression of 
hearing loss after exposure to AGs observed in 
patients with increased genetic susceptibility. 
The strial impairment, furthermore, would 
explain the little effect on vestibular function in 
these patients[38]. Interestingly, the stria 
vascularis demonstrates extensive degeneration 
in syndromal mitochondrial diseases[40]. This 
further supports the hypothesis of the stria 
vascularis as the cochlear cells targeted by the 
mitochondrial mutations in patients with 
increased genetic susceptibility to AG ototoxicity. 
An alternative simple explanation is that 
susceptibility to the mitochondrial disease is a 
function of metabolic demand so that hair cells 
operating at higher frequencies will be more 
susceptible to a reduced mitochondrial function 
than lower frequency cells, that is, cochlea versus 
vestibular, basal versus apical, and type I versus 
type II. Similarly the highly metabolically active 
strial cells would also have increased sensitivity. 
 In genetically susceptible individuals, it is 
postulated that a single injection of AG can cause 
ototoxic damage[41], implying that genetic factors 
can reduce the threshold concentration at which 
AGs cause damage[17]. At higher concentrations or 
more frequent doses of AG, the incidence of 
ototoxic damage exceeds the prevalence of 
genetic predispositions[33,38,42]. Although in vitro, a 
clear relationship between damage and AG 
concentration is observed, the extent of ototoxic 
damage in vivo does not seem to correlate with 
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AG concentration in targeted tissues[43]. This 
discrepancy requires further evaluation. 
Apoptotic Pathways of Ototoxic Hair Cell 
Death 
Inside the hair cell, AGs cause damage, 
either directly or indirectly, by first inducing 
disarray of stereocilia and ultimately ending with 
apoptotic cell death[44–47]. The presence of AGs 
within hair cells leads to increased formation of 
reactive oxygen species (ROS) or free radicals[48–
51]. A common mechanism for the formation of 
ROS is the Fenton reaction:  
Fe2+ +H2O2 −→ Fe3+ +HO• +HO−.  
When gentamicin combines with iron 
salts, the gentamicin-iron complex enhances iron-
catalyzed oxidations and, thereby, directly 
promotes the formation of ROS[48]. This requires 
electrons for which unsaturated fatty acids can 
act as electron donors. In return, those fatty acids, 
predominantly arachidonic acid, are oxidized to 
lipid peroxides[51]. 
The mechanism of involvement of 
mitochondrial mutations in ototoxic hair cell 
death is not completely understood. Exposure to 
AG leads to impairment of RNA translation and 
inhibition of protein synthesis within 
mitochondria[23,26,52]. It is further suggested that 
inhibition of mitochondrial protein synthesis 
leads to a decrease in ATP. With the decrease of 
energy production, the mitochondrial integrity is 
compromised and predispose to a leakage of 
Cytochrome C and subsequent activation of the 
apoptotic cascades. 
Another group of mediators of apoptotic 
hair cell death is the stress-activated protein 
kinases, including the mitogen-activated protein 
(MAP) kinases (Figure 2)[46]. A particular group of 
MAP kinases are c-jun N-terminal kinases (JNK). 
These JNKs are located in the cytoplasm and 
regulated by c-Jun-interacting protein-1 (JIP-
1)[55,56]. In response to cellular insults, JIP-1 
facilitates the phosphorylation and thus 
activation of JNK[57–60]. Activated JNK in turn 
phosphorylates and thereby activates the 
transcription factors c-Jun, c-Fos, ELK-1, and 
activated transcription factor 2 (ATF-2) in the 
nucleus and Bcl-2 in mitochondria[46]. After AG 
treatment, increases in JNK, c-Jun, c-FOS, and Bcl-
2 have been reported in hair cells[46,54,60,61]. 
Activation of the JNK signaling pathway appears 
to precede the release of mitochondrial 
Cytochrome C, which then activates 
caspases[54,62]. Caspases execute cell death in 
apoptosis[53]. 
 Reactive oxygen species (ROS), stress 
kinases, and the caspase family of proteases are 
activated and mediate hair cell degeneration 
caused by aminoglycoside exposure, whereas 
overexpression of Bcl-2 protects against caspase 
activation and hair cell lose. Aminoglycosides 
damage the mitochondria and can result in 
generation of ROS and activation of stress 
kinases. Both ROS and stress kinases can cause 
cell death directly as well as amplify insults 
targeting the mitochondria. The balance between 
pro-apoptotic and anti-apoptotic Bcl-2 family 
membrane determines the integrity of the 
mitochondria. Cytochrome c leaking out of 
damaged mitochondria leads to caspase-9 
activation, which in turn activates caspase-3 to 
execute cell death. 
Efforts in hair cell protection 
 With increasing understanding of ototoxic 
cell death, a myriad of therapeutic efforts have 
been proposed to target various steps of the 
complex cascades to hair cell death. Those 
strategies include inhibition of apoptosis, 
neutralization of ROS, and administration of 
neurotrophic factors. A detailed overview of 
relevant studies including applied drugs, dosage, 
and outcome is presented in a table at the end of 
each subchapter. 
Inhibition of Apoptotic Enzymes[63] 
 Caspase inhibitors conferred significant 
protection against hair cell damage from AG, 
preserving hair cell morphology as well as 
function in vitro and in vivo. Agents targeting 
upstream stress kinases in the apoptotic cascades 
also prevented AG-induced hair cell death. 
Targeting the Bcl-2 family as the upstream key 
mediator of apoptosis also prevented AG-induced 
hair cell loss.  
Neutralization of Reactive Oxygen Species[64]  
 Aminoglycosides form complexes with 
iron, thereby, catalyzing the formation of ROS. 
Competitive blocking of the Fenton reaction 
involved by iron chelators, thus, is a reasonable 
approach to avoid oxidative damage from the 
beginning. Therefore, much efforts aiming at 
prevention of AG-induced hair cell death have 
focused on iron. Administration of the iron 
chelators deferoxamine and 2,3-
dihydroxybenzoate before AG exposure 
significantly attenuated hearing threshold shifts 
and protected from hair cell loss in vivo. 
 Acetylsalicylate (ASA) is another iron 
chelator with additional direct antioxidant 
properties. ASA prevents cleavage of PKC zeta, a 
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key regulator of NFκβ activated by exposure to 
amikacin. N-Acetylcysteine (NAC) is another drug 
commonly used in patients. Beside its mucolytic 
effect, NAC is also a known antioxidant.  
Alternative Otoprotective Strategies[65-74]  
 There exist a number of alternative 
approaches to protect against AG ototoxicity. One 
intriguing approach is moderate exposure to 
ototoxic stimuli with the intent to increase 
intrinsic antioxidant mechanisms within the ear. 
Exposure to low doses of amikacin or gentamicin 
for 30 days and consecutive high-dose treatment 
for another 10 to 12 days resulted in significantly 
less morphologic and functional hair cell damage. 
However, this bears the undesirable risk of 
increased bacterial resistance and, thereby, 
undermines the primary antimicrobial purpose of 
the AG application. Exposure to moderate noise 
also protects from gentamicin ototoxicity in 
gerbils (Table 3). As this does not allow for 
immediate application of AG in therapeutic doses, 
applicability in human patients appears difficult. 
Other studies successfully target NMDA receptors 
to protect auditory nerves. However, the NMDA 
receptor antagonists dizocilpine and ifenprodil 
exist as maleate and tartrate salts, which carry 
intrinsic metal chelating properties. Their vehicle, 
dimethyl sulfoxide (DMSO), can also act as a 
radical scavenger. Therefore, the results of Basile 
and coworkers were challenged by Sha and 
Schacht. Nonetheless, NMDA antagonists do 
interact with receptors of afferent auditory nerve 
fibers. Thus, targeting the auditory nerve appears 
reasonable as AGs interact with certain nerve 
synapses. AGs can aggravate myasthenia gravis 
and cause postoperative respiratory suppression 
suggesting a direct neuromuscular blockade. 
Presynaptically, AGs interfere with the calcium 
internalization essential for acetylcholine release. 
At the postsynaptic level, streptomycin directly 
blocks the acetylcholine receptor primarily, 
whereas neomycin affects the open probability of 
the ion channel of the acetylcholine receptor. 
Also, in rat and mouse cochlear cultures, 
fluorescently tagged gentamicin accumulates in 
the afferent auditory nerve fibers in addition to 
the hair cells. 
 This direct interaction with the auditory 
nerve also might explain therapeutic effects by 
neurotrophic growth factors. Ciliary neurotrophic 
factor (CDNF), glial-cell-line-derived 
neurotrophic factor (GDNF), brain-derived 
neurotrophic factor (BDNF), and neurotrophin 3 
(NT-3) demonstrated partial protective effects 
against AG ototoxicity. The contribution of 
neurotrophic growth factors in preventing AG 
ototoxicity suggests an involvement of the 
auditory nerve. However, there is evidence that 
the effects of neurotrophic growth factors are 
short term. Local application of BDNF (62.5 
μg/mL, 0.25 μL/h over 28 d) to guinea pigs 
exposed to kanamycin (400 mg/kg, single dose, 
s.c.) and furosemide (100 mg/kg, single dose, i.v.) 
demonstrated initial protection from ototoxicity. 
Cessation of the therapy, however, resulted in an 
accelerated neuronal degeneration and after 
another 14 d, the survival of BDNF treated 
auditory neurons did not differ from the 
deafened, untreated control animals. Ethacrynic 
acid (EA) is a diuretic which increases AG 
ototoxicity when administered simultaneously. 
 Delayed co-treatment with application of 
EA 12–18 hr after gentamicin injections in guinea 
pigs resulted in significantly protected hair cell 
function and morphology. The authors suggest 
that EA disrupts the blood-labyrinth barrier, thus 
creating a gradient promoting efflux of AG from 
the inner ear fluids back into the bloodstream. 
However, the protective effects are time 
dependent and could not be found when EA was 
injected 20 hr after the AG. Moreover, 
simultaneous AG and EA in patients resulted in 
ototoxic damage after a single treatment, thereby 
excluding EA as a treatment option. Overall, 
prevention of apoptotic hair cell death following 
AG exposure has been targeted effectively on 
various levels. Direct inhibition of apoptotic 
cascades resulted in functional and 
morphological preservation of hair cells. 
Neutralization of free radicals by antioxidants 
prevented activation of apoptotic enzymes. 
Furthermore, application of NMDA-receptor 
antagonists, neurotrophic growth factors, and 
sound conditioning have prevented ototoxic hair 
cell damage from AG. However, these protective 
results are mainly based on acute studies and the 
sustainability of therapeutic potential and safety 
remains to be evaluated inchronic exposure 
scenarios or in clinical trials. 
Potential targets for hair cell protection[75] 
 The most effective target sites involve the 
mitochondrial rRNA as well as AG entry into the 
inner ear fluids and hair cells. On the level of the 
MET channel, at least two possibilities of 
preventing AG entry exist. The first one involves a 
reversible block of the MET channel. The process 
of hearing requires depolarization of the inner 
hair cell through the MET channel. Blocking of the 
MET channel would then prevent hair cell 
depolarization and, therefore pause hearing 
 Int. J. Ayur. Pharma Research, 2015;3(1):24-36  ISSN: 2322 - 0910 
 Available online at : http://ijapr.in Page 30 
function. Thus, the MET channel block has to be 
temporary. MET channel blockers have been 
tested successfully in vitro. The narrowest part of 
the MET channel pore has been estimated to be 
1.25 nm. As dihydrostreptomycin is capable of 
blocking the MET channel, the difference in the 
dimensions of the MET channel and certain AGs 
appears to be small. Therefore, widening of the 
AG diameter by binding of inert molecules on 
sites irrelevant for antimicrobial activity appears 
a promising strategy to prohibit passage of AGs 
through the MET channel into the hair cells. As 
the passage through the bacterial membrane is 
self-promoting and depends on the relative 
positive charge of the AG, the intended increase 
of size should not affect bacterial uptake of the 
AG as long as the polarity and the charge of the 
new AG molecule remains the same. Another 
target lies in preventing AG from entering the 
inner ear fluids. AGs enter the inner ear fluids 
through the stria vascularis.  
How is ototoxicity diagnosed?[76] 
 The diagnosis is based upon the patient’s 
history, symptoms, and test results. There is no 
specific test for ototoxicity; this makes a positive 
history for ototoxin exposure crucial to the 
diagnosis. Some of the tests that may be used to 
determine how much hearing or balance function 
have been lost involve the vestibular autorotation 
test (VAT), vestibulo-ocular reflex testing 
equipment (VORTEQ), electronystagmography 
(ENG), computerized dynamic posturography 
(CDP), rotary chair (SHAT), head-shaking, 
electrocochleography (EcoG), auditory brainstem 
response (ABR), otoacoustic emissions, pure tone 
audiometry, speech discrimination, and most 
other tests often used to identify and quantify 
inner ear problems. 
What is the treatment?[77] 
 At present there are no treatments that 
can reverse the damage. Currently available 
treatments focus on reducing the effects of the 
damage and rehabilitating function. Specifically, 
individuals with hearing loss may be helped with 
hearing aids; those with profound bilateral (two-
sided) hearing loss have been shown to benefit 
from cochlear implants. In fact, many early 
recipients of cochlear implants were victims of 
ototoxicity. When a loss of balance function has 
occurred, physical therapy can help the brain 
become accustomed to the altered balance signals 
coming from the inner ear. Physical therapy can 
also assist an individual in developing other ways 
to maintain balance such as emphasizing the use 
of vision and proprioception the sensation felt by 
the soles of the feet, the ankles, knees, and hips 
and structuring a program of general physical 
conditioning and exercises designed to 
strengthen and tone muscles. 
The effect of corticosteroid against 
streptomycin ototoxicity[77] 
 The aim of this experimental study was to 
determine the possible protective role of 
corticosteroid in prevention of streptomycin-
induced ototoxicity. Twenty-eight adult Wistar 
albino rats were divided into 4 groups: control (n 
= 7), streptomycin (n = 7), corticosteroid (n = 7), 
and streptomycin + corticosteroid (n = 7). Rats 
were tested with distortion product otoacoustic 
emissions (DPOAEs) in the beginning and at the 
end of the study. The animals in all groups were 
killed under general anesthesia on the 45th day 
after the last DPOAE measurements. Hearing 
results were analyzed statistically to determine 
differences in amplitudes of DPOAE. In addition, 
the cochleas of each rat were evaluated by 
histopathologic and immunohistochemical 
examination. Significant difference was not 
observed in cochlear hair cells in the control and 
corticosteroid groups, whereas severe 
degeneration of hair cells and increased apoptotic 
cells were observed in the streptomycin group. 
Moderate degeneration was observed in the 
streptomycin + corticosteroid group. The hair 
cells were partially intact. DP-gram of the 
streptomycin and streptomycin + corticosteroid 
groups was significantly deteriorated (P < 0.05). 
The co-administration of steroids with 
streptomycin, which has a serious ototoxic effect, 
did not lead to a limitation of this harmful effect. 
The protective role of caffeic acid phenethyl 
ester against streptomycin ototoxicity[78] 
 Caffeic acid phenethyl ester treatment 
attenuated hair cells injury in the inner ear, 
possibly via its antioxidant effect. Prophylactic 
administration of CAPE for streptomycin 
ototoxicity ameliorated hearing deterioration in 
rats. 
Long-term goals[79] 
 The major long-term goals include 
continuing with conditioning activities to 
improve balance function, protecting the other 
systems involved with maintaining balance, and 
preventing further ototoxic damage. 
 Protection of other components of 
balance vision and proprioception is essential. 
Good vision is crucial in the face of a severe 
vestibular loss. Yearly ophthalmological 
examinations that include a glaucoma check 
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should become routine. Use of ultraviolet (UV) 
eye protection in the sun and eye protection in 
the wind (such as goggles or sunglasses) should 
be considered. 
 Protecting proprioception involves taking 
precautions such as avoiding walking barefooted 
on any surface that could injure or damage the 
soles (such as on a macadam road surface), not 
wearing clothing that restricts circulation to the 
legs and feet (such as a tight girdle), and taking 
off excess body weight that can cause knee and 
hip difficulties. 
 Avoidance of ototoxic substances is also 
very important because individuals who have 
suffered from ototoxicity have a higher likelihood 
of experiencing it again, if exposed. A medic alert 
tag might be helpful for warning health care 
professionals about the need to avoid prescribing 
ototoxic medications unless needed to save your 
life. Such tags might also serve to flag an existing 
reduction in balance and/or hearing function. 
A look at the future[80] 
 Ongoing related research addresses 
prevention and treatment. Chemicals are being 
evaluated for their ability to prevent ototoxicity 
and that might be prescribed in tandem with 
ototoxic drugs in the future. Investigators are also 
studying methods of hair-cell and nerve-cell 
regeneration. In the distant future, it may be 
possible to stimulate the ear into growing 
replacement hair cells and to repair damaged 
nerve fibers. 
Endnote[80] 
 Most of the drugs listed in this document 
appear because strong evidence exists to show 
that they cause or probably cause ototoxicity. 
This evidence includes at least one of the 
following criteria: 
 Large numbers of isolated reports about 
particular drugs or chemicals 
 Experiments showing that animals develop 
ototoxicity when given the drug 
 Multiple post-mortem studies that 
demonstrate changes in the ear that are 
linked to ototoxins in people who took 
certain drugs and who subsequently 
developed symptoms of ototoxicity. (Such 
ear damage can only be observed after 
death, when the ears can be examined fully.) 
An example of this type of research is Zheng 
et al, 2001. 
 Scientific reports about groups of people 
tested before (if possible), during, and after 
their use of a drug, some of whom were 
found to develop ototoxicity while taking the 
drug. An example of this type research is 
Black et al, 2001. 
DISCUSSION 
 It is now well known that the 
aminoglycoside antibiotics act synergistically 
with some drugs, thus increasing the incidence of 
ototoxicity. For example, the use of 
aminoglycoside antibiotics with loop diuretics 
can produce an unexpectedly high incidence of 
ototoxicity. This has been extensively 
documented in human case reports as well as in 
animal studies. Ethacrynic acid, an ototoxic loop 
diuretic, has been shown to increase the 
permeability of the stria vascularis, facilitating 
the diffusion of the aminoglycoside into the 
endolymph. Finally, it has been found that 
diuretics given prior to the administration of 
aminoglycosides are less damaging than if done 
in the reverse . Most recently noted is a similar 
response to aminoglycoside antibiotics and the 
use of metronidazole . 
 It is unclear at this time if antiviral and 
protease inhibitors are responsible for the 
anecdotal reporting of neuro-sensory hearing 
loss in patients with human immunodeficiency 
virus. Prospective studies are needed to confirm 
whether nucleoside analog reverse transcriptase 
inhibitor or antiviral agents cause hearing loss in 
this patient population. The use of 
chemoprevention measures as described in 
animal studies show promise, but so far no 
prospective clinical trials have been performed 
and the authors are not aware of any medical 
centers with protocols to address this issue at 
this time. 
CONCLUSION 
 Streptomycin is still recommended as 
first line drug for tuberculosis, Inspite of its 
potential to cause ototoxicity, clinician could use 
it with caution and with the aid of well designed 
system for early monitoring and early 
discontinuation. 
 Hearing loss due to ototoxicity is 
generally irreversible but avoidable in most 
instances, given preventive action through 
rational use of drugs in the health care system 
and by the consumers. 
 There are situations in which potentially 
ototoxic drugs must be administered. Under such 
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circumstances, the following should be observed: 
(i) proper dosage and duration of therapy; (ii) an 
appropriate route of drug administration; (iii) a 
continuous monitoring of the patient, with 
particular attention to audiometric values and 
serum drug level where feasible. 
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Fig: A simplified schematic of the cell of the cell death cascade in hair cells damaged by 
aminoglycosides 
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